ArticleLeukemia2020
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.Frontiers in immunology · 2024Trial
- Trial
- Trial
- COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?Acta haematologica · 2024Review
- Cancer, more than a "COVID-19 co-morbidity".Frontiers in oncology · 2023Review
- Prognostic serum biomarkers in cancer patients with COVID-19: A systematic review.Translational oncology · 2022Article
- Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.Oncology letters · 2021Review
- Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.Cancers · 2021Article
- Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges.Leukemia research reports · 2021Review
- A Case of COVID-19-Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated?Clinical lymphoma, myeloma & leukemia · 2021Article
- Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.Acta haematologica · 2021Review
- The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.Therapeutic advances in hematology · 2021Review
- Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions.Mediterranean journal of hematology and infectious diseases · 2021Article
- Article
- Immunologic characterization of COVID-19 patients with hematological cancer.Haematologica · 2020Article
- When CLL meets COVID-19.Blood · 2020Article
- Article
- How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic.HemaSphere · 2020Review
- Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia.British journal of haematology · 2020Article
- Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts.Mediterranean journal of hematology and infectious diseases · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.